Assessing Harms When Comparing Medical Interventions

Comparative Effectiveness Reviews are systematic reviews of existing research on the effectiveness, comparative effectiveness, and harms of different health care interventions. They provide syntheses of relevant evidence to inform real-world health care decisions for patients, providers, and policymakers. Strong methodologic approaches to systematic review improve the transparency, consistency, and scientific rigor of these reports. Through a collaborative effort of the Effective Health Care (EHC) Program, the Agency for Healthcare Research and Quality (AHRQ), the EHC Program Scientific Resource Center, and the AHRQ Evidence-based Practice Centers have developed a Methods Guide for Comparative Effectiveness Reviews. This Guide presents issues key to the development of Comparative Effectiveness Reviews and describes recommended approaches for addressing difficult, frequently encountered methodological issues. The Methods Guide for Comparative Effectiveness Reviews is a living document, and will be updated as further empiric evidence develops and our understanding of better methods improves. Comments and suggestions on the Methods Guide for Comparative Effectiveness Reviews and the Effective Health Care Program can be made at www.effectivehealthcare.ahrq.gov. The findings and conclusions in this document are those of the authors, who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ, the Assess all important harms, whenever possible. Use multiple sources of information, including clinical experts and stakeholders, to identify important harms. Use consistent and precise terminology when reporting data on harms, and avoid terms implying causality unless causality is reasonably certain. Gather evidence on harms from a broad range of sources, including observational studies, particularly when clinical trials are lacking; when generalizability is uncertain; or when investigating rare, long-term, or unexpected harms. Do not assume studies adequately assess harms because methods used to assess and report benefits are appropriate; rather, evaluate how well studies identify and analyze harms. Be cautious about drawing conclusions on harms when events are rare and estimates of risk are imprecise. Include placebo-controlled trials, particularly for assessing uncommon or rare harms, but be cautious about relying on indirect comparisons to judge comparative risks, and evaluate whether studies being considered for indirect comparisons meet assumptions for consistency of treatment effects. Avoid inappropriate combining of data on harms, and thoroughly investigate inconsistent results. Introduction Comparative Effectiveness Reviews (CERs) are systematic reviews that evaluate evidence on alternative interventions in order to help clinicians, policymakers, and patients make informed treatment choices. 1 To generate balanced results and conclusions, it is important for CERs to …

[1]  N. Dreyer,et al.  Registries for Evaluating Patient Outcomes: A User’s Guide , 2010 .

[2]  R. Rosenthal,et al.  Selective publication of antidepressant trials and its influence on apparent efficacy. , 2008, The New England journal of medicine.

[3]  P. Santaguida,et al.  The development of the McHarm quality assessment scale for adverse events , 2008 .

[4]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.

[5]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies , 2007, The Lancet.

[6]  S. Pocock,et al.  Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration , 2007, PLoS medicine.

[7]  Kathleen N Lohr,et al.  Emerging Methods in Comparative Effectiveness and Safety: Symposium Overview and Summary , 2007, Medical care.

[8]  Andrew Herxheimer,et al.  Systematic reviews of adverse effects: framework for a structured approach , 2007, BMC medical research methodology.

[9]  Til Stürmer,et al.  Performance of propensity score calibration--a simulation study. , 2007, American journal of epidemiology.

[10]  S. Goodman,et al.  Reproducible Research: Moving toward Research the Public Can Really Trust , 2007, Annals of Internal Medicine.

[11]  G. Guyatt,et al.  Association between unreported outcomes and effect size estimates in Cochrane meta-analyses. , 2007, JAMA.

[12]  R. Chou,et al.  Methodological shortcomings predicted lower harm estimates in one of two sets of studies of clinical interventions. , 2007, Journal of clinical epidemiology.

[13]  Roger Chou,et al.  Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses , 2006, The Lancet.

[14]  E. Ding,et al.  Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. , 2006, JAMA.

[15]  J. Emberson,et al.  Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials , 2006, BMJ : British Medical Journal.

[16]  Paul M Ridker,et al.  Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005. , 2006, JAMA.

[17]  P. Armstrong,et al.  Transition from meeting abstract to full-length journal article for randomized controlled trials. , 2006, JAMA.

[18]  John P.A. Ioannidis,et al.  Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies , 2006, Canadian Medical Association Journal.

[19]  B. Giraudeau,et al.  Reporting of drug tolerance in randomized clinical trials: when data conflict with authors' conclusions. , 2006, Annals of internal medicine.

[20]  A. Avins,et al.  Brief Communication: Better Ways To Question Patients about Adverse Medical Events , 2006, Annals of Internal Medicine.

[21]  J. Aronson,et al.  Case reports of suspected adverse drug reactions—systematic literature survey of follow-up , 2006, BMJ : British Medical Journal.

[22]  Douglas G Altman,et al.  Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. , 2006, JAMA.

[23]  Matthew H Samore,et al.  The Research on Adverse Drug Events and Reports (RADAR) project. , 2005, JAMA.

[24]  J. Grauer,et al.  Industry Support and Correlation to Study Outcome for Papers Published in Spine , 2005, Spine.

[25]  S. Normand,et al.  Reader's guide to critical appraisal of cohort studies: 1. Role and design , 2005, BMJ : British Medical Journal.

[26]  J. Avorn,et al.  A review of uses of health care utilization databases for epidemiologic research on therapeutics. , 2005, Journal of clinical epidemiology.

[27]  R Garside,et al.  Do the findings of case series studies vary significantly according to methodological characteristics? , 2005, Health technology assessment.

[28]  M. Egger,et al.  Risk of cardiovascular events and rofecoxib: cumulative meta-analysis , 2004, The Lancet.

[29]  B. Strom Potential for conflict of interest in the evaluation of suspected adverse drug reactions: a counterpoint. , 2004, JAMA.

[30]  B. Psaty,et al.  Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. , 2004, JAMA.

[31]  J. Ioannidis,et al.  Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement , 2004, Annals of Internal Medicine.

[32]  Anne-Marie Bagnall,et al.  Bmc Medical Research Methodology Open Access Assessing Harmful Effects in Systematic Reviews , 2022 .

[33]  J. Vandenbroucke Benefits and harms of drug treatments , 2004, BMJ : British Medical Journal.

[34]  M. McDonagh,et al.  Hyperbaric oxygen therapy for traumatic brain injury: a systematic review of the evidence. , 2004, Archives of physical medicine and rehabilitation.

[35]  Bruce M Psaty,et al.  Detection, verification, and quantification of adverse drug reactions , 2004, BMJ : British Medical Journal.

[36]  G. Guyatt,et al.  Grading quality of evidence and strength of recommendations , 2004, BMJ : British Medical Journal.

[37]  A. Hrõbjartsson,et al.  Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. , 2004, JAMA.

[38]  Jan P Vandenbroucke,et al.  When are observational studies as credible as randomised trials? , 2004, The Lancet.

[39]  J. Aronson,et al.  A comparison of three different sources of data in assessing the frequencies of adverse reactions to amiodarone. , 2004, British journal of clinical pharmacology.

[40]  Peter Fonagy,et al.  Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data , 2004, The Lancet.

[41]  D. Spiegelhalter,et al.  Systematic qualitative review of the literature on data monitoring committees for randomized controlled trials , 2004, Clinical trials.

[42]  R. Leone,et al.  Upper Gastrointestinal Bleeding Associated with the Use of NSAIDs Newer Versus Older Agents , 2004 .

[43]  R. Leone,et al.  Upper Gastrointestinal Bleeding Associated with the Use of NSAIDs , 2004, Drug safety.

[44]  T. Carey,et al.  A Critical Guide to Case Series Reports , 2003, Spine.

[45]  Jeffrey K Aronson,et al.  Anecdotes as evidence , 2003, BMJ : British Medical Journal.

[46]  Douglas G Altman,et al.  Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses , 2003, BMJ : British Medical Journal.

[47]  Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events v3.0 (CTCAE) , 2003 .

[48]  J. Sterne,et al.  How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study. , 2003, Health technology assessment.

[49]  D. Beek,et al.  Dexamethasone in adults with bacterial meningitis , 2002 .

[50]  Robert C. G. Martin,et al.  Quality of Complication Reporting in the Surgical Literature , 2002, Annals of surgery.

[51]  P. Shekelle,et al.  A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. , 2002, The Journal of rheumatology.

[52]  N McKoy,et al.  Systems to rate the strength of scientific evidence. , 2002, Evidence report/technology assessment.

[53]  Jeffrey K Aronson,et al.  Adverse drug reactions: keeping up to date , 2002, Fundamental & clinical pharmacology.

[54]  G. K. Chambers,et al.  Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. , 2001, JAMA.

[55]  Sheena Derry,et al.  BMC Clinical Pharmacology BioMed Central BMC 1 2001, Clinical Pharmacology , 2001 .

[56]  Jonathan A C Sterne,et al.  Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. , 2001, BMJ.

[57]  J. Ioannidis,et al.  Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. , 2001, JAMA.

[58]  R Day,et al.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.

[59]  I. Edwards,et al.  Adverse drug reactions: definitions, diagnosis, and management , 2000, The Lancet.

[60]  R. Makuch,et al.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. , 2000, JAMA.

[61]  M. Egger,et al.  The hazards of scoring the quality of clinical trials for meta-analysis. , 1999, JAMA.

[62]  B. Psaty,et al.  Assessment and Control for Confounding by Indication in Observational Studies , 1999, Journal of the American Geriatrics Society.

[63]  D. Cook,et al.  Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? , 1998, The Lancet.

[64]  J. Ioannidis,et al.  Quantitative Synthesis in Systematic Reviews , 1997, Annals of Internal Medicine.

[65]  J. Olié,et al.  68-4 Risk/benefit ratio , 1997, Biological Psychiatry.

[66]  S D Walter,et al.  The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. , 1997, Journal of clinical epidemiology.

[67]  J. Ware,et al.  Equivalence trials. , 1997, The New England journal of medicine.

[68]  J. Slattery,et al.  A systematic review of the risks of stroke and death due to endarterectomy for symptomatic carotid stenosis. , 1996, Stroke.

[69]  B Begaud,et al.  False-positives in spontaneous reporting: should we worry about them? , 1994, British journal of clinical pharmacology.

[70]  S. Goodman,et al.  The Use of Predicted Confidence Intervals When Planning Experiments and the Misuse of Power When Interpreting Results , 1994, Annals of Internal Medicine.

[71]  G. Danan,et al.  Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. , 1993, Journal of clinical epidemiology.

[72]  P. Easterbrook,et al.  Publication bias in clinical research , 1991, The Lancet.

[73]  L. Knodel,et al.  Comparison of three algorithms used to evaluate adverse drug reactions. , 1986, American journal of hospital pharmacy.

[74]  H. Morgenstern,et al.  Epidemiologic Research: Principles and Quantitative Methods. , 1983 .

[75]  G. Venning Validity of anecdotal reports of suspected adverse drug reactions: the problem of false alarms , 1982, British medical journal.

[76]  D. Rubin Estimating causal effects of treatments in randomized and nonrandomized studies. , 1974 .

[77]  M. Graffar [Modern epidemiology]. , 1971, Bruxelles medical.